Insider Trading Alert - FLXS, MNRK And ALXN Traded By Insiders

Yesterday, Oct. 29, 2015, 52 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $23.06 to $107,831,600.00.

Highlighted Stocks Traded by Insiders:

Flexsteel Industries (FLXS) - FREE Research Report

Hall Timothy E, who is S.V.P. C.F.O. at Flexsteel Industries, sold 3,735 shares at $44.72 on Oct. 29, 2015. Following this transaction, the S.V.P. C.F.O. owned 30,000 shares meaning that the stake was reduced by 11.07% with the 3,735-share transaction.

The shares most recently traded at $43.14, down $1.58, or 3.67% since the insider transaction. Historical insider transactions for Flexsteel Industries go as follows:

  • 4-Week # shares bought: 1,705
  • 4-Week # shares sold: 2,865
  • 12-Week # shares bought: 1,705
  • 12-Week # shares sold: 2,865
  • 24-Week # shares bought: 1,705
  • 24-Week # shares sold: 48,698

The average volume for Flexsteel Industries has been 41,200 shares per day over the past 30 days. Flexsteel Industries has a market cap of $335.8 million and is part of the consumer goods sector and consumer durables industry. Shares are up 31.81% year-to-date as of the close of trading on Thursday.

Flexsteel Industries, Inc., together with its subsidiaries, manufactures, imports, and markets residential and commercial upholstered and wood furniture products in the United States. The stock currently has a dividend yield of 1.59%. The company has a P/E ratio of 15.1. Currently, there are no analysts who rate Flexsteel Industries a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on FLXS - FREE

TheStreet Quant Ratings rates Flexsteel Industries as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, solid stock price performance, impressive record of earnings per share growth and attractive valuation levels. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook. Get the full Flexsteel Industries Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Monarch Financial Holdings (MNRK) - FREE Research Report

Patterson Elizabeth T, who is Director at Monarch Financial Holdings, sold 876 shares at $12.95 on Oct. 29, 2015. Following this transaction, the Director owned 85,175 shares meaning that the stake was reduced by 1.02% with the 876-share transaction.

The shares most recently traded at $13.14, up $0.19, or 1.45% since the insider transaction. Historical insider transactions for Monarch Financial Holdings go as follows:

  • 4-Week # shares bought: 150
  • 4-Week # shares sold: 11,300
  • 12-Week # shares bought: 150
  • 12-Week # shares sold: 11,300
  • 24-Week # shares bought: 150
  • 24-Week # shares sold: 11,300

The average volume for Monarch Financial Holdings has been 6,100 shares per day over the past 30 days. Monarch Financial Holdings has a market cap of $137.6 million and is part of the financial sector and banking industry. Shares are down 4.15% year-to-date as of the close of trading on Thursday.

Monarch Financial Holdings, Inc. operates as the bank holding company for Monarch Bank that provides various commercial and retail banking products and services for businesses, professionals, corporate executives, and individuals. The stock currently has a dividend yield of 2.78%. The company has a P/E ratio of 11.3. Currently, there is 1 analyst who rates Monarch Financial Holdings a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on MNRK - FREE

TheStreet Quant Ratings rates Monarch Financial Holdings as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, increase in net income, good cash flow from operations, growth in earnings per share and expanding profit margins. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results. Get the full Monarch Financial Holdings Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Alexion Pharmaceuticals (ALXN) - FREE Research Report

Islam Saqib, who is EVP, Chief Strat & Port. Off. at Alexion Pharmaceuticals, sold 1,558 shares at $168.44 on Oct. 29, 2015. Following this transaction, the EVP, Chief Strat & Port. Off. owned 38,310 shares meaning that the stake was reduced by 3.91% with the 1,558-share transaction.

The shares most recently traded at $175.90, up $7.46, or 4.24% since the insider transaction. Historical insider transactions for Alexion Pharmaceuticals go as follows:

  • 4-Week # shares bought: 500
  • 4-Week # shares sold: 812
  • 12-Week # shares bought: 500
  • 12-Week # shares sold: 3,760
  • 24-Week # shares bought: 500
  • 24-Week # shares sold: 36,437

The average volume for Alexion Pharmaceuticals has been 1.8 million shares per day over the past 30 days. Alexion Pharmaceuticals has a market cap of $39.9 billion and is part of the health care sector and drugs industry. Shares are down 4.91% year-to-date as of the close of trading on Thursday.

Alexion Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes life-transforming therapeutic products. The company has a P/E ratio of 60.5. Currently, there are 12 analysts who rate Alexion Pharmaceuticals a buy, no analysts rate it a sell, and 3 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on ALXN - FREE

TheStreet Quant Ratings rates Alexion Pharmaceuticals as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, reasonable valuation levels, increase in net income and good cash flow from operations. We feel its strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full Alexion Pharmaceuticals Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

More from Markets

Tuesday Turnaround: Google Gets Grilled

Tuesday Turnaround: Google Gets Grilled

Nvidia Shares Fall as SoftBank Reportedly Plans to Sell Its Stake

Nvidia Shares Fall as SoftBank Reportedly Plans to Sell Its Stake

Stocks End Mixed as China Trade Progress Offsets D.C. Dysfunction

Stocks End Mixed as China Trade Progress Offsets D.C. Dysfunction

Market Madness: This Market Is for Stock Pickers

Market Madness: This Market Is for Stock Pickers

Jim Cramer: The Operative Term for This Tape Is Treacherous

Jim Cramer: The Operative Term for This Tape Is Treacherous